article thumbnail

Aseptic packaging market to value $35bn by 2033

European Pharmaceutical Review

According to a report by Research Nester, the global aseptic packaging market is projected to reach a revenue of $35 billion by 2033 and is estimated to reach a compound annual growth rate (CAGR) of 10 percent between 2023 and 2033. The post Aseptic packaging market to value $35bn by 2033 appeared first on European Pharmaceutical Review.

Packaging 105
article thumbnail

Pharmapack Awards 2024 entries open

European Pharmaceutical Review

CPHI’s awards provide insight into the industry’s latest developments and innovations that will influence global drug delivery and packaging in the year ahead. This award is open to entries from products or services in either the proof of concept or prototype stage with a timeline for launch until the end of 2026.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Can holograms help in the frontline fight against pharmaceutical counterfeiting?

European Pharmaceutical Review

One area in which the problem can be tackled effectively is product packaging. With predictions that the global market for anticounterfeiting packaging is set to reach almost $250 billion by 2026, growth in authentication and anti-tamper devices such as holograms appear to have a healthy future.”

Packaging 111
article thumbnail

FDA grants approval for Fresenius-Formycon’s biosimilar Otulfi

Pharmaceutical Business Review

The latest FDA approval for Otulfi is based on a detailed assessment of the comprehensive data package which comprised pre-clinical, analytical, clinical and manufacturing findings. A human monoclonal antibody, Ustekinumab acts on the interleukin-12 and interleukin-23 cytokines which hold a key role in inflammatory and immune responses.

article thumbnail

Novo Nordisk to expand French production facilities

European Pharmaceutical Review

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. Novo Nordisk declared that it will help to boost its global capacity, “from manufacturing of active pharmaceutical ingredients (API) through to packaging.” Construction has already begun.

article thumbnail

Construction starts on $400m biosimilars production centre in Slovenia

European Pharmaceutical Review

The centre, which will create up to 330 new jobs in the region, is expected to be operational by the end of 2026. The new biosimilars production centre will also include facilities for manufacturing and storage. The site employs 775 people full time, Sandoz said.

article thumbnail

EU tax compliance proposals to streamline business investment

European Pharmaceutical Review

Transfer pricing proposal As part of the EC’s package of initiatives to reduce tax compliance costs, there is a proposal specifically aimed at harmonising transfer pricing rules in the EU. SMEs are also set to benefit, although the rules will be discretionary.